Abstract
Three males aged 71 to 80 years with known stage IV metastatic prostate cancer underwent F-18 sodium fluoride (NaF) PET/CT to assess osseous metastatic disease burden and stability. In addition to F-18 NaF avid known osseous metastases, each patient also exhibited increased F-18 NaF activity in soft tissues. The first patient exhibited multiple F-18 NaF avid enlarged retroperitoneal and pelvic lymph nodes on consecutive PET/CT scans. The second patient demonstrated an F-18 NaF avid thyroid nodule on consecutive PET/CT scans. The third patient exhibited increased F-18 NaF activity in a hepatic metastasis.
References
Segall G, Delbeke D, Stabin MG, Even-Sapir E, Fair J, Sajdak R, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813–20.
Sabbah N, Jackson T, Mosci C, Jamali M, Minamimoto R, Quon A, et al. 18F-sodium fluoride PET/CT in oncology: an atlas of SUV’s. Clin Nucl Med. 2015;40:e228–31.
Sheth S, Colletti PM. Atlas of sodium fluoride PET bone scans: atlas of NaF PET bone scans. Clin Nucl Med. 2012;37:e110–6.
Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59:1539–48.
Yoon DY, Chang SK, Choi CS, Yun EJ, Seo YL, Nam ES, et al. The prevalence and significance of incidental thyroid nodules identified on computed tomography. J Comput Assist Tomogr. 2008;32:810–5.
Shie P, Cardarelli R, Sprawls K, Fulda KG, Taur A. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30:742–8.
Chun AR, Jo HM, Lee SH, Chun HW, Park JM, Kim KJ, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Endocrinol Metab (Seoul). 2015;30:71–7.
Basu S, Kembhavi S. Serendipitous observation of hepatic metastases on (18)F-fluoride PET in a patient with infiltrating ductal carcinoma of breast: correlation with contrast enhanced CT. Clin Nucl Med. 2012;37:1176–8.
Swietaszczyk C, Prasad V, Baum RP. Intense 18F-fluoride accumulation in liver metastases from a neuroendocrine tumor after peptide receptor radionuclide therapy. Clin Nucl Med. 2012;37:e82–3.
Wong KK, Piert M. Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: mechanisms and applications. J Nucl Med. 2013;54:590–9.
Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med. 2001;31:50–61.
Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633–42.
Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, et al. The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med. 2012;53:1175–84.
Valdes-Martinez A, Kraft SL, Brundage CM, Arceneaux BK, Stewart JA, Gibbons DS. Assessment of blood pool, soft tissue, and skeletal uptake of sodium fluoride F 18 with positron emission tomography-computed tomography in four clinically normal dogs. Am J Vet Res. 2012;73:1589–95.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Andrew Hawkins and Brandon Howard declare that they have no conflict of interest relevant to the work described herein.
Ethical Statement
This report of three patients did not constitute human subjects research according to the standards of the Duke Institutional Review Board (IRB) (https://irb.duhs.duke.edu/policies-and-regulations/policies) and was exempt from IRB review.
Rights and permissions
About this article
Cite this article
Hawkins, A.S., Howard, B.A. Unusual Soft Tissue Uptake of F-18 Sodium Fluoride in Three Patients Undergoing F-18 NaF PET/CT Bone Scans for Prostate Cancer. Nucl Med Mol Imaging 51, 274–276 (2017). https://doi.org/10.1007/s13139-016-0420-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-016-0420-2